Women treated with glucagon-like peptide 1 (GLP-1) receptor agonists had a lower rate of cardiovascular events than men.181 Clinical trials showed that the combination of exenatide and metformin can improve insulin sensitivity, lower insulin resistance, and blood lipid levels, and increase adiponectin levels, which was more beneficial for female patients with type 2 diabetes than male. This evidence concerns the gene INS and type 2 diabetes mellitus.